Efficacy and safety evaluation of HLX10 (a recombinant humanized anti-PD-1 monoclonal antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy: A single-arm, open-label, phase 2 study.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Hunan Cancer Hospital, Nanjing Drum Tower Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Hubei Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, Liaoning Cancer Hospital & Institute, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3196537296